Biotech Values

[mcbio]

Given that two competing drugs-ABBV/ENTA and GILD's-are hitting the HCV treatment market at the same time, there must be a finite chance that a third one could also arise, and severely reduce both pricing and sales. Have you given any thought to this in your model?

There's no finite chance; it's pretty much a certainty that several additional competing all-oral combos will come to market in the years following the GILD and ABBV/ENTA all-oral entries (MRK, BMY, JNJ to name a few).